GraniteShares YieldBOOST CRCL 

$22.26
17
+$0.79+3.66% Today

Statistics

Day High
22.29
Day Low
22.2
52W High
25.93
52W Low
21.48
Volume
5,804
Avg. Volume
3,787
Mkt Cap
874.96M
P/E Ratio
-
Dividend Yield
94.4%
Dividend
21.01

Upcoming

Dividends

94.4%Dividend Yield
Jul 26
$0.40
Jul 26
$0.40
Jun 26
$0.40
Jun 26
$0.40
Jun 26
$0.40
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

9FebExpected
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
-0.18
-0.03
0.11
0.26
Expected EPS
-0.1
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CRY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Artivion Inc., established in 1984 and based in Kennesaw, Georgia, functions globally as a manufacturer, processor, and distributor of both medical devices and implantable human tissues. Previously known as CryoLife, Inc., the company underwent a rebranding to Artivion Inc. in January 2022. Artivion caters to a wide array of clients, including physicians, hospitals, various healthcare facilities, and specialized surgeons in cardiac, vascular, thoracic, and general fields. Their comprehensive product portfolio features BioGlue, a polymer formulated from bovine blood protein for use in cardiac, vascular, pulmonary, and general surgical procedures. They also provide the On-X line of prosthetic aortic and mitral heart valves, alongside the On-X ascending aortic prosthesis. Artivion extends its services to include cardiac preservation and offers PhotoFix, a bovine pericardial patch, as well as the E-vita OPEN PLUS and E-vita OPEN NEO hybrid stent graft systems. The company is a prominent supplier of specialized stent grafts designed for numerous aortic and arterial conditions. These include the E-xtra DESIGN ENGINEERING products for aortic vascular diseases, E-nside as an off-the-shelf option for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular treatment of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, E-ventus BX for renal and pelvic arteries, E-liac for aneurysmal iliac arteries and their side branches, and E-tegra for abdominal aortic aneurysms. Further offerings encompass synthetic vascular grafts for open aortic and peripheral surgeries, PerClot (an absorbable powdered hemostat), and cardiac laser therapy equipment such as the SolarGen 2100s Console. They also provide CryoVein and CryoArtery vascular preservation services, CarbonAid CO2 diffusion catheters, Chord-X ePTFE sutures for mitral chordal replacement, and ascyrus medical dissection stents. Additionally, Artivion provides pyrolytic carbon coating services to other manufacturers in the medical device industry.
Show more...
CEO
Employees
1200
Country
United States
ISIN
US38747T6661

Listings

0 Comments

Share your thoughts

FAQ

What is GraniteShares YieldBOOST CRCL stock price today?
The current price of CRY is $22.26 USD — it has increased by +3.66% in the past 24 hours. Watch GraniteShares YieldBOOST CRCL stock price performance more closely on the chart.
What is GraniteShares YieldBOOST CRCL stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange GraniteShares YieldBOOST CRCL stocks are traded under the ticker CRY.
What is GraniteShares YieldBOOST CRCL market cap?
Today GraniteShares YieldBOOST CRCL has the market capitalization of 874.96M
Does GraniteShares YieldBOOST CRCL pay dividends?
Yes, CRY dividends are paid weekly. The last dividend per share was 0.4 USD. As of today, Dividend Yield (FWD)% is 94.4%.
How many employees does GraniteShares YieldBOOST CRCL have?
As of June 15, 2026, the company has 1,200 employees.
In which sector is GraniteShares YieldBOOST CRCL located?
GraniteShares YieldBOOST CRCL operates in the Other sector.
When did GraniteShares YieldBOOST CRCL complete a stock split?
GraniteShares YieldBOOST CRCL has not had any recent stock splits.